Q2 2024 Cognition Therapeutics Inc Earnings Call Transcript
Key Points
- Cognition Therapeutics Inc (CGTX) reported a 39% slowing of cognitive decline in the SHINE trial for Alzheimer's disease, which is higher than the 25-30% seen with recently approved monoclonal antibodies.
- The SHINE trial demonstrated a favorable safety and tolerability profile for CT1812, with most adverse events being mild or moderate.
- The company has a strong financial position with $28.5 million in cash and cash equivalents and $57.3 million in remaining grant funds from the NIA.
- Cognition Therapeutics Inc (CGTX) is actively pursuing multiple clinical trials, including the SHIMMER trial for dementia with Lewy bodies and the MAGNIFY study for age-related macular degeneration.
- The company is leveraging non-dilutive funding from the NIH to support its clinical programs, demonstrating efficient financial management.
- The SHINE trial did not achieve statistical significance on the ADAS-Cog 11 scale, indicating the need for larger and longer trials.
- Research and development expenses increased to $11.6 million in Q2 2024 from $8.5 million in the same period in 2023, reflecting higher costs associated with advancing clinical programs.
- The company reported a net loss of $7 million for Q2 2024, compared to a net loss of $4.7 million in Q2 2023.
- There were treatment-emergent liver function test increases at the 300-milligram dose in the SHINE trial, although these resolved without serious liver injuries.
- The cash runway is only sufficient to fund operations into the second quarter of 2025, necessitating future funding strategies to support later-stage trials.
Hello, and thank you for standing by. At this time, I would like to welcome you to the Cognition Therapeutics second-quarter 2024 earnings call. (Operator Instructions)
I would now like to turn the conference over to Tom Johnson. Please go ahead.
Thank you, operator, and good morning, everyone. Welcome to the Cognition Therapeutics second-quarter 2024 results conference call. With me today are Lisa Ricciardi, President and Chief Executive Officer; John Doyle, Chief Financial Officer; and Tony Caggiano, Chief Medical Officer.
This morning, the company issued a press release detailing its financial results for the second quarter and first half of the 2024 fiscal year. We encourage everyone to read this morning's press release as well as Cognition's quarterly report on Form 10-Q, annual report on Form 10-K and periodic reports on Form 8-K, which are now filed with the SEC and available on our website. In addition, this conference call is being webcast through the company's website and will be archived for
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
